Celcuity Inc. (CELC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US15102K1007
Celcuity Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -172.19 m USD |
| EBIT | -172.19 m USD |
| Net income | -177.04 m USD |
| Diluted EPS – continuing operations | -3.79 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
More stocks
- SEACOAST BANKING CORP OF FLORIDA (SBCF)
- Chengdu Xingrong Investment Co Ltd (000598.SZ)
- Hexpol AB (HPOL B.ST)
- Venture Corporation Ltd (V03.SI)
- Knife River Corp (KNF)
- Ferrotec (Anhui) Technology Development Co. Ltd. A (301297.SZ)
- Fastly, Inc. (FSLY)
- Ondas Inc. (ONDS)
- China Railway Construction Heavy Industry Corp Ltd (688425.SS)
- Regis Resources Ltd (RRL.AX)
- Zhejiang Huazheng New Material (603186.SS)
- Farsoon Technology Co. Ltd. A (688433.SS)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.